Background/Aims: Through conceptualising poor insight in psychotic disorders as a form of anosognosia, frontal lobe dysfunction is often ascribed a vital role in its pathogenesis. The objective of this study was to compare the relation of insight in patients with psychotic illness to that of psychopathology and frontal lobe function. Methods: Forty patients with psychotic disorder were selected from those attending the Department of Psychiatry in a tertiary care teaching hospital. The evaluation of insight was carried out using the Schedule for Assessment of Insight (SAI), that of frontal lobe function by the Frontal Assessment Battery (FAB) and psychopathology by the Brief Psychiatric Rating Scale (BPRS). The correlation coefficients were determined. Results: A negative correlation between SAI and BPRS scores means that the BPRS score is opposite to SAI scores. When the SAI total score was compared with the FAB total score, the correlation coefficient demonstrated a positive correlation. Better insight predicted lesser psychopathology and also that poor insight would exist with greater psychopathology. Better insight predicted a higher functional status of frontal lobes and prefrontal cortex in particular. Conclusion: Insight deficits in schizophrenia and other psychotic illnesses are multidimensional. Integration of different aetiological factors like biological, psychopathological, environmental ones and others are necessary for a better understanding of insight in psychosis.

Keywords:
Compliance, ICD-10, Insight, Psychopathology, Psychotic disorders, Schizophrenia
1.
Raffard S, Bayard S, Capdevielle D, Garcia F, Boulenger JP, Gely-Nargeot MC: Lack of insight in schizophrenia: a review. Encéphale 2008;34:511-516.
2.
David A, van Os J, Jones P, Harvey I, Foerster A, Fahy T: Insight and psychotic illness. Cross-sectional and longitudinal associations. Br J Psychiatry 1995;167:621-628.
3.
Buchy L, Ad-Dab'bagh Y, Malla A, Lepage C, Bodnar M, Joober R, Sergerie K, Evans A, Lepage M: Cortical thickness is associated with poor insight in first-episode psychosis. J Psychiatr Res 2011;45:781-787.
4.
Smith TE, Hull JW, Goodman M, Hedayat-Harris A, Willson DF, Israel LM: The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. J Nerv Ment Dis 1999;187:102-108.
5.
Lysaker PH, Bell MD, Bryson G, Kaplan E: Neurocognitive function and insight in schizophrenia: support for an association with impairments in executive function but not with impairments in global function. Acta Psychiatr Scand 1998;97:297-301.
6.
Smith TE, Hull JW, Israel LM, Willson DF: Insight, symptoms, and neurocognition in schizophrenia and schizoaffective disorder. Schizophr Bull 2000;26:193-200.
7.
McEvoy JP, Freter S, Merritt M, Apperson LJ: Insight about psychosis among outpatients with schizophrenia. Hosp Community Psychiatry 1993;44:883-884.
8.
Cuesta MJ, Peralta V: Lack of insight in schizophrenia. Schizophr Bull 1994;20:359-366.
9.
David AS, Buchanan A, Reed A, Almeida O: The assessment of insight in psychosis. Br J Psychiatry 1992;161:599-602.
10.
Simon V, De Hert M, Wampers M, Peuskens J, van Winkel R: The relation between neurocognitive dysfunction and impaired insight in patients with schizophrenia. Eur Psychiatry 2009;24:239-243.
11.
Saravanan B, Jacob KS, Johnson S, Prince M, Bhugra D, David AS: Assessing insight in schizophrenia: East meets West. Br J Psychiatry 2007;190:243-247.
12.
World Health Organization: ICD-10 Classification of Diseases and Related Health Problems (ICD-10). Geneva, World Health Organization, 1992.
13.
Dubois B, Slachevsky A, Litvan I, Pillon B: The FAB: a frontal assessment battery at bedside. Neurology 2000;55:1621-1626.
14.
Blacker D: Psychiatric rating scales; in Sadock BJ, Sadock VA (eds): Kaplan and Sadock's Comprehensive Textbook of Psychiatry, ed 3. Philadelphia, Lippincott Williams & Wilkins, 2005, pp 938-943.
15.
Sanz M, Constable G, Lopez-Ibor I, Kemp R, David AS: A comparative study of insight scales and their relationship to psychopathological and clinical variables. Psychol Med 1998;28:437-446.
16.
Wing JK, Cooper JE, Sartorius N: Measurement and classification of psychiatric symptoms. Cambridge, Cambridge University Press, 1974.
17.
Mintz AR, Dobson KS, Romney DM: Insight in schizophrenia: a meta-analysis. Schizophr Res 2003;61:75-88.
18.
McEvoy JP, Apperson LJ, Appelbaum PS: Insight in schizophrenia: its relationship to acute psychopathology. J Nerv Ment Dis 1989;177:43-47.
19.
Bora E: Theory of mind in schizophrenia spectrum disorders. Turk Psikiyatri Derg 2009;20:269-281.
20.
Cooke MA, Peters ER, Kuipers E, Kumari V: Disease, deficit or denial? Models of poor insight in psychosis. Acta Psychiatr Scand 2005;112:4-17.
21.
Arduini L, Kalyvoka A, Stratta P, Rinaldi O, Daneluzzo E, Rossi A: Insight and neuropsychological function in patients with schizophrenia and bipolar disorder with psychotic features. Can J Psychiatry 2003;48:338-341.
22.
McEvoy JP, Hartman M, Gottlieb D, Godwin S, Apperson LJ, Wilson W: Common sense, insight, and neuropsychological test performance in schizophrenia patients. Schizophr Bull 1996;22:635-641.
23.
Aleman A, Agrawal N, Morgan KD, David AS: Insight in psychosis and neuropsychological function: meta-analysis. Br J Psychiatry 2006;189:204-212.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.